ClinicalTrials.gg
CompletedNCT06814132Updated Oct 23, 2025

A Study to Evaluate the Effect of MK-5684 in Male Participants With Severe Renal Impairment (RI) and With End-stage Renal Disease (ESRD) (MK-5684-010)

A Phase 1 interventional study of MK-5684 and Prednisone in Kidney Failure, Chronic, End-Stage Kidney Disease and Renal Failure, Chronic, sponsored by Merck Sharp & Dohme LLC. Completed at 2 sites in United States. Open to male participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-10-23.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Oct 2025, 1 year 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years to 85 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Kidney Failure, Chronic by Merck & Co., Inc — none open to participants now, none under way, none of them phase 3. Kidney Failure, Chronic · Merck & Co., Inc.

Enrollment
4th of 12
24 · median 18
Started
2025
the only one that year
Phase 1
10 of 12
none open now
Registered
11th of 12
by date

Among the 12 studies in Kidney Failure, Chronic by Merck & Co., Inc, this one is the 4th largest by enrollment, is the only one that started in 2025, is one of 10 in phase 1, and was the 11th registered.

Kidney Failure, Chronic

2,112 studies on the registry are indexed under Kidney Failure, Chronic; 274 are open to participants now.

Browse Kidney Failure, Chronic studies →

Open to participants now

None of the 12 studies in Kidney Failure, Chronic by Merck & Co., Inc is open now. The open studies under Kidney Failure, Chronic, anywhere →

Who these studies take

Of the 169 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.

This study: 18 Years to 85 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies in Kidney Failure, Chronic by Merck & Co., Inc as a file.
02

Study summary

The goal of the study is to learn what happens to levels of MK-5684 in people with severe renal impairment and end-stage renal disease versus a healthy person's body over time. Researchers will compare what happens to MK-5684 after hemodialysis in people with severe renal impairment and end-stage renal disease versus healthy people.

03

Conditions studied

  • Kidney Failure, Chronic
  • End-Stage Kidney Disease
  • Renal Failure, Chronic
  • Renal Failure, End-Stage
  • Healthy Participants
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Inclusion criteria include, but are not limited to:

All Participants

  • Is a continuous non-smoker or moderate smoker (≤ 10 cigarettes per day or equivalent) for at least 3 months prior to the first dosing
  • Has a (BMI) ≥ 18.0 and ≤ 42.0 kg/m\^2 at the screening visit

Participants with severe renal impairment (RI) (Group 1):

  • Has severely impaired renal function as determined by estimated (eGFR) using the 2021 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation

Participants with end-stage renal disease (ESRD) (Group 2):

  • Has ESRD maintained on stable outpatient regimen of intermittent high-flux hemodialysis (HD) (at least 3 times per week) for a minimum of 3 hours per dialysis session, using a complication free well-maintained arteriovenous fistula or arteriovenous graft, for at least 3 months prior to first dosing and is expected and planning to continue HD during the study and at least up to the follow-up visit

Healthy Control Participants (Group 3):

  • Has normal renal function

Exclusion criteria

Exclusion Criteria:

Exclusion criteria include, but are not limited to:

All Participants:

  • Has a history or presence of any of the following: Adrenal insufficiency; Hepatic impairment; hypotension; cardiac arrhythmia; cardiac conduction abnormalities or recurrent unexplained syncopal events; Second- or third-degree atrioventricular (AV) heart block (except in participants with a functional artificial pacemaker); Clinically significant sick sinus syndrome; Any systemic fungal infection; Hypothyroidism; Chronic infection
  • Has a first-degree relative with multiple unexplained syncopal events, unexplained cardiac arrest, or sudden cardiac death, or has a known family history of an inherited arrhythmia syndrome (including Brugada syndrome)
  • Has a history of cancer ()
  • Is positive for (HIV), surface antigen (HBsAg), or virus (HCV)

Participants with Severe RI (Group 1):

  • Has a history or presence of renal artery stenosis
  • Has had a renal transplant
  • Has ESRD requiring HD

Participants with ESRD (Group 2):

  • Has required frequent emergent HD (≥ 3) within a year prior to the first dosing
  • Has a history or presence of renal artery stenosis.
  • Has had a functioning renal transplant within the past 2 years
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Group 1: Severe Renal Impairment (RI)

    Participants will receive a single oral dose of MK-5684 under fasting conditions (on an empty stomach after a 10-hour overnight fast) on Day 1 and a single dose of Hormone replacement therapy (HRT) (prednisone and fludrocortisone) administered approximately 4.5 hours after MK-5684 dosing under fed conditions (eating a normal meal).

    Drug: MK-5684 · Drug: Prednisone · Drug: Fludrocortisone acetate

  • Experimental
    Group 2: End-stage renal disease (ESRD)

    Participants will receive a single oral dose of MK-5684 under fasting conditions (on an empty stomach after a 10-hour overnight fast) in Period 1 and Period 2. In Period 1, participants will receive a single oral dose of MK-5684 approximately 30 minutes prior to their normally scheduled hemodialysis (HD), followed by HRT under fed conditions (eating a normal meal) 4.5 hours after MK-5684 dosing. In Period 2, participants will receive a single oral dose of MK-5684 immediately followed by completion of their normally scheduled HD, and by HRT under fed conditions (eating a normal meal) 4.5 hours after MK-5684 dosing.

    Drug: MK-5684 · Drug: Prednisone · Drug: Fludrocortisone acetate

  • Experimental
    Group 3: Healthy Participants

    Participants will receive a single oral dose of MK-5684 under fasting conditions (on an empty stomach after a 10-hour overnight fast) on Day 1 and a single dose of Hormone replacement therapy (HRT) (prednisone and fludrocortisone) administered approximately 4.5 hours after MK-5684 dosing under fed conditions (eating a normal meal).

    Drug: MK-5684 · Drug: Prednisone · Drug: Fludrocortisone acetate

Interventions

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration Versus Time Curve from 0 to Infinity (AUC0-inf) After a Single Dose of MK-5684

    Blood samples will be collected to determine the AUC0-inf of MK-5684 in plasma.

    Time frame: At protocol specific time points pre-dose and up to 72 hours post-dose

  2. Area Under the Concentration Versus Time Curve From 0 to the Time of the Last Quantifiable Sample (AUC0-last) of MK-5684

    Blood samples will be collected to determine the AUC0-last of MK-5684 in plasma.

    Time frame: At protocol specific time points pre-dose and up to 72 hours post-dose

  3. Area Under the Concentration Versus Time Curve From 0 to 24 Hours After Dosing (AUC0-24) of MK-5684

    Blood samples will be collected to determine the AUC0-24 of MK-5684 in plasma.

    Time frame: At protocol specific time points pre-dose and up to 24 hours post-dose

  4. Maximum Observed Drug Concentration (Cmax) After the Administration of a Given Dose of MK-5684

    Blood samples will be collected to determine the Cmax of MK-5684 in plasma.

    Time frame: At protocol specific time points pre-dose and up to 72 hours post-dose

  5. Time to Maximum Observed Plasma Drug Concentration (Tmax) of MK-5684

    Blood samples will be collected to determine the Tmax of MK-5684 in plasma.

    Time frame: At protocol specific time points pre-dose and up to 72 hours post-dose

  6. Apparent Terminal Half-Life (t½) of MK-5684

    Blood samples will be collected to determine the t1/2 of MK-5684 in plasma.

    Time frame: At protocol specific time points pre-dose and up to 72 hours post-dose

  7. Apparent Clearance (CL/F) of MK-5684

    Blood samples will be collected to determine the CL/F of MK-5684 in plasma.

    Time frame: At protocol specific time points pre-dose and up to 72 hours post-dose

  8. Apparent Volume of Distribution During Terminal Phase (Vz/F) of MK-5684

    Blood samples will be collected to determine the Vz/F of MK-5684 in plasma.

    Time frame: At protocol specific time points pre-dose and up to 72 hours post-dose

Secondary outcomes

  1. Number of Participants who Experience an Adverse Event (AE)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of the study intervention, whether or not considered related to the study intervention.

    Time frame: Up to ~21 days

  2. Number of Participants who Discontinue Study Intervention Due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of the study intervention, whether or not considered related to the study intervention.

    Time frame: Up to ~7 days

  3. Dialysis Clearance (CLD) of MK5684 Based on Plasma

    Dialysate will be collected to determine the CLD of MK-5684 in plasma.

    Time frame: At protocol specific time points pre-dose and up to 4.5 hours post-dose

  4. Concentration of Dialysate (CD) of MK-5684 Samples

    Dialysate will be collected to determine the CD of MK-5684 in plasma.

    Time frame: At protocol specific time points pre-dose and up to 4.5 hours post-dose

  5. Amount of drug (AD) of MK-5684 recovered from each dialysate collection

    Dialysate will be collected to determine the AD of MK-5684 in plasma.

    Time frame: At protocol specific time points pre-dose and up to 4.5 hours post-dose

07

Study locations

2 sites
  • Orlando Clinical Research Center ( Site 0002)
    Orlando, Florida 32809, United States
  • Research by Design ( Site 0001)
    Chicago, Illinois 60643, United States
08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2025 to primary completion in Oct 2025, 5 months.

Of 46 industry-sponsored phase 1 interventional studies under Kidney Failure, Chronic, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's 5 months is below that.

Counting every sponsor, half of 67 studies reached it within 12 months; a quarter within 5 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2025
First posted
Feb 7, 2025
StartActual
Apr 7, 2025
Primary completionActual
Oct 4, 2025
CompletionActual
Oct 14, 2025
Last update
Oct 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06814132
Responsible party
Sponsor
First posted
Feb 7, 2025
Start date
Apr 7, 2025
Primary completion
Oct 4, 2025
Completion
Oct 14, 2025
Last update
Oct 23, 2025

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Opevesostat

Start the discussion